Место фулвестранта в эндокринотерапии метастатического рака молочной железы

1. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991; 51: 3867–73.
2. Howel A, Pippen J, Elledge RM et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospective planned combined survival analysis of two multicenter trials. Cancer 2005; 104: 236–9.
3. Vergote I, Robertson JFR. Fulvestrant is an effective and welltolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials. Br J Cancer 2004; 90 (Suppl. 1): S11–4.
4. Howel A, Robertson JFR, Abram P et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multination, double-blind, randomized trial. J Clin Oncol 2004; 22: 1605–13.
5. Vergote I, Abram P. Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. Ann Oncol 2006; 17: 200–4.
6. Perey L, Thurlimann B, Hawle H et al. Fulvestrant (‘faslodex’) as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and Aromatase inhibitors [abstract]. Breast Cancer Res Treat 2004; 88 (Suppl. 1): S236. (Abstr 6048).
7. Ingle JN, Rowland KM, Suman VJ et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: a phase II trial of the North Central Cancer Treatment Group [abstract]. Breast Cancer Res Treat 2004; 88 (Suppl. 1): S38. Abstract 409.
8. Steger GG, Gips M, Simon SD et al. Fulvestrant (‘Faslodex’): clinical experience from the Compassionate Use Programme. Cancer Treat Rev 2005; 31: S10–6.
9. Robertson JFR, Howell A, Gorbunova VA et al. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. Breast Cancer Res Treat 2005; 92: 169–74.
10. Vergote I, Robertson JFR, Kleeberg U et al. Postmenopausal women who progress on fulvestrant (‘Faslodex’) remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003; 79: 207–11.
11. Johnston S. Fulvestrant and the sequential endocrine cascade for advanced breast cancer. Br J Cancer 2004; 90 (Suppl. 1): S15–8.
12. DeFriend DJ, Howell A, Nicholson RI et al. Investigation of a new pure antiestrogen (ICI 182,780) in women with primary breast cancer. Cancer Res 1994; 54: 408–14.
13. Howell A, DeFriend D, Robertson J et al. Response to a specific antiestrogen (ICI 182,780) in tamoxifen-resistant breast cancer. Lancet 1995; 345: 29–30.
14. Howell A, DeFriend DJ, Robertson JF et al. Pharmacokinetics, pharmacological, and anti-tumour effects of the specific anti-oestrogen ICI 182,780 in women with advanced breast cancer. Br J Cancer 1996; 74: 300–8.
15. Robertson JF, Blamey RW, Howell A et al. Duration of response to ICI 182,780 appears significantly longer than «Megace» in tamoxifen-resistant breast cancer [abstract]. Breast Cancer Res Treat 1996; 37 (Suppl.): 33.
16. Ellis MJ, Hayes DF, Lippman ME. Treatment of metastatic breast cancer. In Harris JR, ed. Diseases of the Breast, 2nd edn. Philadelphia, Lippincott Williams & Wilkins, 2000; 749–97.
17. Kuerer HM, Buzdar AU, Singletary SE. Biologic basis and evolving role or aromatase inhibitors in the management of invasive carcinoma of the breast. J Surg Oncol 2001; 77: 139–47.
18. Dombernowsky P, Smith I, Falkson G et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453–61.
19. Addo S, Yates RA, Laight A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer 2002; 87: 1354–9.
20. Mauriac L, Pippen JE, Quaresma Albano J et al. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer 2003; 39: 1228–33.
21. Robertson JF, Osborne CK, Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women – A prospective combined analysis of two multicenter trials. Cancer 2003; 98: 229–38.
22. Pippen J, Osborne CK, Howell A, Robertson JFR. Fulvestrant (Faslodex) versus anastrozole (Arimidex) for the treatment of advanced breast cancer: a prospective combined survival analysis of two multicenter trials. Breast Cancer Res Treat 2003; 82 (Suppl. 1): S101 (Abstr 426).
23. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451–67.
24. Bonneterre J, Buzdar A, Nabholtz JM et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92: 2247–58.
25. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the international letrozole breast cancer group. J Clin Oncol 2001; 19: 2596–606.
26. Fisher B, Costantino JP, Redmond CK et al. Endometrial cancer in tamoxifentreated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project NSABP) B-14. J Natl Cancer Inst 1994; 86: 527–37.
27. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J Clin Oncol 2003; 21: 2101–9.
28. Buzdar A, Robertson JFR, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation Aromatase inhibitors anastrozole, letrozole and exemestane. Cancer 2002; 95: 2006–16.
29. Donnellan PP, Douglas SL, Cameron DA, Leonard RC. Aromatase inhibitors and arthralgia. J Clin Oncol 2001; 19: 2767.
30. Paridaens R, Dirix L, Lohrisch C et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003; 14: 1391–8.
31. Paridaens R, Therasse P, Dirix L et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) – A randomized phase III trial of the EORTC Breast group. Proc Am Soc Clin Oncol 2004; 23: 6 (Abstr 515).
32. Buzdar A, Jonat W, Howell A et al. Anastrozole, a potent and selective Aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 1996; 14: 2000–11.
33. Wiseman LR, Adkins JC. Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer. Drugs Aging 1998; 13: 321–32.
34. Lamb HM, Adkins JC. Letrozole. A review of its use in postmenopausal women with advanced breast cancer. Drugs 1998; 56: 1125–40.
35. Rose C, Vtoraya O, Pluzanska A et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003; 39: 2318–27.
36. Buzdar A. Exemestane in advanced breast cancer. Anticancer Drugs 2000; 11: 609–16.
37. Michaud LB, Buzdar AU. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer. Drug Saf 1999; 21: 297–309.
38. Thurlimann B, Paridaens R, Serin D et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. Eur J Cancer 1997; 33: 1767–73.
39. Bergman L, Beelen ML, Gallee MP et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres’ ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 2000; 356: 881–7.
40. Vergote I et al. Metastatic breast cancer:sequencing hormonal therapy and positioning of fulvestrant. Int J Gynecol Cancer 2006; 16 (Suppl. 2): 524–6.

И.В.Колядина, Н.П.Макаренко, И.В.Поддубная

Кафедра онкологии ГОУ ДПО РМАПО, Москва